RPAM
SMMT icon

Rhenman & Partners Asset Management’s Summit Therapeutics SMMT Stock Holding History

Rhenman & Partners Asset Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-78,000
Closed -$1.66M – 100
2025
Q2 		$1.66M Buy
+78,000
New +$1.78M 0.21% 75

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
ACL
APEIRON Capital Ltd Hong Kong $107M AUM 9.59% 1-Year Est. Return

Rhenman & Partners Asset Management's SMMT Position: Q3 2025 in Review

Rhenman & Partners Asset Management sold out of Summit Therapeutics (SMMT) in Q3 2025, closing a stake of 78,000 shares — an estimated $1.66M sold.

Rhenman & Partners Asset Management first reported a position in SMMT in Q2 2025 and held it in 1 quarter. The position peaked at $1.66M in Q2 2025. 232 funds tracked by Wall St. Rank hold SMMT as of Q3 2025.

  • Rhenman & Partners Asset Management reported no remaining Summit Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Rhenman & Partners Asset Management sold 78,000 Summit Therapeutics shares in Q3 2025, an estimated $1.66M.
  • Rhenman & Partners Asset Management first reported a position in Summit Therapeutics in Q2 2025 and held it in 1 quarter.
  • Rhenman & Partners Asset Management's Summit Therapeutics position peaked at $1.66M in Q2 2025.
  • 232 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2025.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.